Trinean appoints new CEO and secures 2.7 million euro financing

03-May-2012 - Belgium

Trinean NV announced the appointment of Philippe Stas as it’s new CEO, succeeding Dr. Marc Zabeau, who remains a member of the board of directors. Simultaneously, Trinean announced that the company has secured 2.7 million euro of growth financing provided by its existing investors.

Prior to joining Trinean, Philippe Stas was CEO of Algonomics NV, a Belgium based biotech service provider, where he ensured the growth and subsequent trade sale of the company to Lonza Group AG in 2009. Since then, he was the director and main driver of Lonza’s Applied Protein Services division in Cambridge (UK). Earlier, Philippe Stas held positions at Perkin Elmer and Keygene. Philippe holds a M.Sc. in Bio-engineering (Brussels Univ.), a M.Sc. in Information Technology (Hasselt Univ.), an MBA (Univ. of Liverpool) and AMP at the Vlerick Management School.

Trinean raised 2.7 million euro to further accelerate the development of its premium analytical platform, comprising highly accurate spectrophotometry instruments, state-ofthe-art analytical software, proprietary disposables for standardized micro-volume sample analysis and highly flexible lab-automation tools.

https://www.bionity.com/en/news/137715/trinean-appoints-new-ceo-and-secures-2-7-million-euro-financing.html